Pharmaceuticals

Vyndaqel Market Size and Demand Forecast 2026–2030

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the vyndaqel market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Vyndaqel Market be in 2030 compared with 2026?

The vyndaqel market size has experienced rapid expansion in recent years. It is projected to expand from $1.9 billion in 2025 to $2.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.4%. Factors contributing to this growth historically include the approval of tafamidis, the scarcity of effective ATTR-CM treatments, advancements in cardiac imaging diagnostics, the proliferation of rare disease initiatives, and an increase in cardiology referrals.

The vyndaqel market is projected to experience substantial expansion in the coming years, with forecasts indicating it will reach $4.19 billion by 2030, driven by a compound annual growth rate (CAGR) of 17.1%. This growth during the projected timeframe can be attributed to an expanding elderly demographic, heightened understanding of amyloid cardiomyopathy, the proliferation of specialized cardiology centers, increased uptake of genetic testing, and enhanced reimbursement assistance. Key trends anticipated in this period encompass the wider acceptance of transthyretin stabilizers, a surge in the diagnosis of ATTR cardiomyopathy, the development of oral treatments for uncommon heart conditions, a heightened emphasis on cardiac medications that modify disease progression, and the greater application of sustained amyloidosis therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21321&type=smp

What Drivers Are Guiding Growth Patterns In The Vyndaqel Market?

The future expansion of the Vyndaqel market is anticipated due to the increasing integration of precision medicine. This medical strategy customizes treatment for individual patients by taking into account their genetic, environmental, and lifestyle elements, which leads to better treatment efficacy and patient outcomes. The embrace of precision medicine is expanding because both patients and healthcare professionals increasingly prefer tailored therapies that offer precise treatment and more effective management of chronic illnesses. Vyndaqel complements precision medicine by providing a targeted therapy for transthyretin amyloidosis (ATTR), thus ensuring that the most suitable patients receive the medication. For example, in February 2024, the US Food and Drug Administration (FDA) gave its approval to 16 novel personalized therapies for rare disease patients in 2023, a notable rise from 6 in 2022, as stated by the US-based non-profit organization, the Personalized Medicine Coalition. This growing adoption of precision medicine is consequently propelling the Vyndaqel market’s growth.

Which Segments Are Driving Activity In The Vyndaqel Market?

The vyndaqel market covered in this report is segmented –

1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)

2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

What Trends Are Reshaping The Dynamics Of The Vyndaqel Market?

Leading companies in the vyndaqel market are prioritizing facility expansions to manufacture active pharmaceutical ingredients, specifically transthyretin stabilizing therapeutics, aiming to improve cardiovascular outcomes and reduce hospitalizations for patients with ATTR-CM. A transthyretin stabilizing therapeutic is a pharmacological agent engineered to bind and stabilize transthyretin (TTR) tetramers, which prevents their dissociation into misfolded monomers that accumulate to form amyloid deposits. For example, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company focused on genetic diseases, introduced Attruby (acoramidis), a near-complete (=90%) transthyretin (TTR) stabilizer developed to address key issues in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) operates by binding and stabilizing TTR tetramers, thereby stopping their breakdown into misfolded monomers that generate amyloid deposits in cardiac tissue. This treatment provides considerable cardiovascular benefits, including a decrease in cardiovascular death and cardiovascular-related hospitalizations, while preserving TTR’s native physiological functions, making it an effective intervention for enhancing patient results and managing the disease in ATTR-CM.

Which Leading Companies Dominate The Vyndaqel Market Share?

Major companies operating in the vyndaqel market are Pfizer Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/vyndaqel-global-market-report

How Does The Vyndaqel Market Perform Across Major Global Regions?

North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Vyndaqel Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21321&type=smp

Browse Through More Reports Similar to the Global Vyndaqel Market 2026, By The Business Research Company

Virtual Assistant Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Virtual Data Room Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-data-room-global-market-report

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795